Company Overview and News

1
CBS Corp's Showtime Networks names new chief financial officer

2018-10-19 marketwatch
CBS Corp's CBS, +2.01% Showtime Networks, whose programs include "Shameless," "Billions" and the upcoming comedy "Black Monday" about the Wall Street crash of 1987, announced Friday it has named Adam Townsend to the position of executive vice president and chief financial officer. Townsend will be replacing Christina Spade, who now serves as chief financial officer and executive vice president of Showtime parent CBS.
CBS CBS.A CPV CBS.WD

1
UPDATE 1-Rihanna turns down Super Bowl show, backs Kaepernick

2018-10-19 reuters
LOS ANGELES (Reuters) - Pop superstar Rihanna declined an offer to perform at a Super Bowl halftime show because she supported former National Football League quarterback Colin Kaepernick and his protest against racial injustice, according to media reports.
CBS CBS.A CPV CBS.WD

1
Outfront Media Starts OOH Campaign for Movember Foundation

2018-10-19 zacks
Outfront Media Inc. (OUT - Free Report) recently initiated an out-of-home advertising campaign in collaboration with the Movember Foundation. The primary motive of the campaign is to raise awareness about Movember — the Foundation's annual campaign that raises funds and spreads awareness about men's health, focusing on prostate cancer, testicular cancer, suicide prevention and mental health. The advertisement features the campaign slogan 'Grow a Mo, Save a Bro', highlighting the foundation’s emphasis to prevent unnecessary and early death within the male population.
CBS CBS.A CPV CBS.WD CCO OUT

8
PRESS DIGEST -Wall Street Journal - Oct 19

2018-10-19 reuters
Oct 19 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
CBS CBS.A CPV CBS.WD DWDP

1
PRESS DIGEST-New York Times business news - Oct 19

2018-10-19 reuters
Oct 19 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.
CBS CBS.A NYTAB CPV CBS.WD

3
Negative Sentiment In Entercom Communications Is Misconceived

2018-10-15 seekingalpha - 1
Entercom Communications Corp (ETM) is the second largest terrestrial radio broadcasting company in the United States. As a ‘traditional media’ business, it is subject to the prevailing market view that its business is in terminal decline, whilst ‘new media’ companies like Spotify Technology SA (SPOT) are expected to grow to the sky (and are priced by the market accordingly). At the present share price, the market is implying that the decline in Entercom’s business will be rapid.
CBS CMLSQ LSXMB BATRK CMLS FWONB CBS.A LSXMA BATRR ETM.WI CMIA CBS.WD ETM FWONA CMLSW FWONK BATRB LSXMK CPV BATRA

95
16 Stocks to Buy Before They Turn It Around

2018-10-12 investorplace - 6
In any market — bull or bear — investors can always find turnaround stocks to buy. Companies are no more perfect than the humans that comprise them, after all. Mergers go south. Poor management can decimate morale. Sometimes, the world changes — and it takes a few years for a business to catch up.
LOW JCP CHKVP UAA CHKVZ TTS BHC SHLD NKE KMI VSI KMR CVB GE FTD CBS.WD CMG GPRO MAT CHK VZ CPV BATRA FTR LSXMB HD FIT BATRK CPB LSXMA FND BATRR CHKDH CHKDG VZA CHKDJ VRX CHKDP FTRPR GRMN AAPL BATRB CBS VIA CKRGZ GEC FWONB CBS.A QRTEA M FLWS FWONA CHKWZ UA HAS CHK.WI KHC FWONK GNE LSXMK KMRFZ DHR

2
CORRECTED-CBS to look for potential buyers after Moonves probe ends - Fox journalist

2018-10-09 reuters
(Corrects first paragraph to say CBS is a “broadcast and media” company, not a “cable” company)
CBS VIA CBS.A VIAB CPV CBS.WD

2
CBS to look for potential buyers after Moonves probe ends: Fox journalist

2018-10-08 channelnewsasia
CBS Corp would look for potential buyers for the cable company after a probe on its former Chief Executive Officer Leslie Moonves ends, a Fox journalist tweeted on Monday.
CBS VIA CBS.A VIAB CPV CBS.WD

2
CBS to look for potential buyers after Moonves probe ends: Fox journalist

2018-10-08 reuters
(Reuters) - CBS Corp (CBS.N) would look for potential buyers for the cable company after a probe on its former Chief Executive Officer Leslie Moonves ends, a Fox journalist tweeted on Monday.
CBS VIA CBS.A VIAB CPV CBS.WD

2
CBS to look for potential buyers after Moonves probe ends - Fox journalist

2018-10-08 reuters
Oct 8 (Reuters) - CBS Corp would look for potential buyers for the cable company after a probe on its former Chief Executive Officer Leslie Moonves ends, a Fox journalist tweeted on Monday.
CBS VIA CBS.A VIAB CPV CBS.WD

1
Key Words: Susan Collins thinks Ford was ‘mistaken’ in accusing Kavanaugh of sexual assault

2018-10-08 marketwatch
Sen. Susan Collins said Sunday that she was “very comfortable” with voting to confirm Brett Kavanaugh to the U.S. Supreme Court, despite the sexual-assault allegations leveled against him by Christine Blasey Ford.
CBS CBS.A CPV CBS.WD

23
6 Stocks Set for Monster Growth in 2019

2018-10-06 investorplace - 2
Although stocks have experienced a rough start so far in 2018, some stocks still have a big chance to shine this year. The best stocks to buy now go above and beyond the normal growth prospects. While looking for these kinds of investments, I examined six of the best stocks to invest in, all with huge upside potential and support from the Street’s top analysts.
CBS CLDR CBS.A NBIX PLAY CPV CBS.WD SBGI LAUR

1
CBS executive placed on leave after accusations of sexual language

2018-10-03 channelnewsasia
CBS Corp has placed television executive Vincent Favale on leave after earlier allegations of using sexual and homophobic language resurfaced, the company said on Wednesday.
CBS CBS.A CPV CBS.WD

1
CBS executive placed on leave after accusations of sexual language

2018-10-03 reuters
(Reuters) - CBS Corp (CBS.N) has placed television executive Vincent Favale on leave after earlier allegations of using sexual and homophobic language resurfaced, the company said on Wednesday.
CBS CBS.A CPV CBS.WD

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...